Why a proteomic panel predicts cardiovascular death in heart failure far better than NT-proBNP alone. UK Biobank (N ≈ 500,000)

KEY INSIGHT

NT-proBNP is the standard prognostic marker for heart failure, yet on its own it captures only one axis of a multi-dimensional syndrome. A multi-protein signature discovered by Aurora roughly doubles the hazard ratio for cardiovascular death (HR 3.50 vs 1.77 per SD) and lifts prognostic discrimination to C-index 0.76. Panel-level discovery captures signal that any single assay misses.

The Limit of a Single Marker

NT-proBNP is the canonical readout of cardiac congestion, and it is genuinely prognostic: stratifying heart failure patients by NT-proBNP tertile gives a hazard ratio of 1.77 per SD (95% CI 1.62–1.93, log-rank p = 2.7e-26). But one analyte measures one process. At 15 years, the high-NT-proBNP tertile still has roughly 65% survival versus about 87% in the low tertile, a separation of around 22 percentage points. Useful, but it leaves most of the prognostic picture untold.

A Panel Tells the Fuller Story

 

A multi-protein Cox signature roughly doubles the hazard ratio to 3.50 (95% CI 3.18–3.85, log-rank p = 1.3e-86) and widens 15-year survival separation between high- and low-risk tertiles to about 46 percentage points (roughly 48% vs 94% survival). The panel resolves risk that NT-proBNP alone cannot.

 

Stratifier	NT-proBNP alone	Multi-protein model
Hazard ratio (per SD)	1.77	3.50
95% CI	1.62–1.93	3.18–3.85
15-yr survival, low vs high tertile	~87% vs ~65%	~94% vs ~48%
Log-rank p	2.7e-26	1.3e-86

 

 

Proteins Carry the Prognostic Signal

Proteomics alone takes discrimination from a C-index of 0.60 (baseline demographics) to 0.74, almost matching the best multimodal model at 0.76. Adding clinical labs and polygenic risk scores contributes only a little more. For a prognostic test, a proteomic panel is close to sufficient on its own.

 

What the Panel Detects

The discovered proteins span the distinct biological processes that drive heart failure progression, which is why they add up to more than NT-proBNP:

Process	Representative panel proteins
Congestion / wall stress	NT-proBNP, ANGPT2
RAAS / renal perfusion	Renin, EDN1
Fibrosis / tissue remodelling	SPON1, HGF, SCGB3A1
Metabolic / systemic stress	ANGPTL4, GDF-15, REG4

 

Why It Matters for Trials and Diagnostics

A panel-based prognostic test enriches trials and stratifies patients far more sharply than a single analyte, concentrating events and improving statistical power. Aurora discovers and validates these signatures on population-scale data, then ports them to other endpoints by changing the cohort definition. The result is a faster route from biomarker hypothesis to a defensible, multi-protein prognostic readout.